Biopharmaceutical R&D remained resilient in 2025, with investment and dealmaking increasingly concentrated in high value science, emerging biopharma, and China linked activity. At the same time, growing scientific complexity, longer development timelines, and persistent regional disparities in drug availability and trial country utilization have put pressure on productivity, elevating the importance of internal efficiency levers and regulatory reform in sustaining and enhancing innovation and competitiveness.